Vigabatrin
- 1 May 1999
- Vol. 40 (s5), s11-s16
- https://doi.org/10.1111/j.1528-1157.1999.tb00914.x
Abstract
Vigabatrin (VGB) is a structural analogue of the inhibitory neurotransmitter gamma-amino butyric acid (GABA), which produces its antiepileptic effect by irreversibly inhibiting the degradative enzyme GABA-transaminase. This produces an increase in central nervous system (CNS) GABA levels. VGB is among the few antiepileptic drugs (AEDs) that was synthesized with a specific targeted mechanism in mind and was subsequently demonstrated to function by that mechanism. Tiagabine, a GABA reuptake blocker, is the only other "designer drug" among the currently available AEDs. Therefore, VGB is among the few AEDs for which the mechanism of action is well understood. Recently, safety issues have been raised with regard to the use of vigabatrin. This article reviews the mechanism of action, pharmacokinetics, safety, and efficacy of VGB.Keywords
This publication has 72 references indexed in Scilit:
- Letter to the editor Fatal hepatotoxicity in a child treated with vigabatrinActa Neurologica Scandinavica, 2009
- Pharmacokinetic Interactions Between Antiepileptic DrugsClinical Pharmacokinetics, 1996
- Human Brain γ‐Aminobutyric Acid Levels and Seizure Control Following Initiation of Vigabatrin TherapyJournal of Neurochemistry, 1996
- Vigabatrin as Initial Therapy for Infantile Spasms: A European Retrospective SurveyEpilepsia, 1996
- Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imagingEpilepsy Research, 1994
- VigabatrinDrugs, 1991
- Vigabatrin and behaviour disturbancesThe Lancet, 1990
- γ‐Vinyl GABA: A double‐blind placebo‐controlled trial in partial epilepsyAnnals of Neurology, 1985